{"id":519893,"date":"2021-07-29T08:25:25","date_gmt":"2021-07-29T12:25:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-reports-boosting-immune-responses-in-subjects-previously-vaccinated-by-a-vaxart-vaccine\/"},"modified":"2021-07-29T08:25:25","modified_gmt":"2021-07-29T12:25:25","slug":"vaxart-reports-boosting-immune-responses-in-subjects-previously-vaccinated-by-a-vaxart-vaccine","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxart-reports-boosting-immune-responses-in-subjects-previously-vaccinated-by-a-vaxart-vaccine\/","title":{"rendered":"Vaxart Reports Boosting Immune Responses in Subjects Previously Vaccinated by a Vaxart Vaccine"},"content":{"rendered":"
\n

First booster clinical study by Vaxart shows boosted immune responses similar to original responses with Vaxart vaccine<\/h2>\n

Findings have potential implications for Vaxart’s COVID-19 oral vaccine program<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n SOUTH SAN FRANCISCO, Calif.<\/span>, July 29, 2021<\/span> \/PRNewswire\/ —\u00a0Vaxart, Inc. (Nasdaq: VXRT) today\u00a0announced\u00a0that\u00a0it has shown for\u00a0the first time in clinical trials that its oral tablet vaccine\u00a0platform successfully\u202fboosted\u00a0immune responses in\u00a0subjects\u00a0previously vaccinated\u00a0with a Vaxart oral vaccine\u00a0more than\u00a0a year earlier.<\/p>\n

\n

\n
\n \"Vaxart,
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Vaxart is a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection.\u00a0Vaxart’s\u00a0programs are based on its proprietary oral vaccine platform called VAAST.\u00a0\u00a0\u00a0<\/p>\n

“These results are very important because they support our belief that our oral tablet vaccines have the potential to be used\u00a0repeatedly for indications that may require an annual boost, such as flu, COVID-19, or norovirus,” said Andrei Floroiu<\/span>, Vaxart’s Chief Executive Officer.\u00a0“We are excited by these findings and by the implications for all of our vaccines.”<\/p>\n

“Using our oral norovirus vaccine candidate, we successfully boosted the immune responses of those previously vaccinated with our platform,”\u00a0said Dr. Sean Tucker<\/span>, Vaxart’s founder and Chief Scientific Officer. “We believe these results could have implications for the other vaccines we are developing, including our oral COVID-19 vaccine tablet, because they are all based on the same platform and use the same vector.<\/p>\n

“Moreover,” Dr. Tucker said, “this clinical evidence has the potential to differentiate our vaccines from injectable\u00a0vector-based\u00a0vaccines.\u00a0Typically, when you inject viral vector-based vaccines, they generate immune responses against the against the viral vector as well as the intended antigens.<\/p>\n

“Anti-vector\u00a0antibodies from the injected vaccine immune response may\u00a0prevent the viral vector from serving as a boosting agent.\u00a0\u00a0Our norovirus trial results suggest that Vaxart’s vaccines may\u00a0not be hampered by certain antibody response challenges that can occur with injectable viral vector-based vaccines.”\u00a0\u00a0 <\/p>\n

The data came from\u00a0Vaxart’s\u00a012-subject Phase 1b\u00a0blinded\u00a0study\u00a0evaluating the\u00a0ability of its norovirus vaccine to\u00a0boost\u00a0immunogenicity. Study participants were initially vaccinated with\u00a0Vaxart’s\u00a0oral norovirus vaccine in late 2019 and\u00a0were\u00a0vaccinated again between February and April 2021.\u00a0\u00a0<\/p>\n

All seven participants\u00a0who\u00a0had been\u202fpreviously immunized with the oral norovirus vaccine elicited\u202fa\u202fsimilar\u202fbroad range of\u202fimmune responses\u202fto\u00a0norovirus\u00a0as the five subjects that had not received a prior oral vaccine dose.\u202f\u202f\u00a0\u00a0<\/p>\n

“We will continue to evaluate the capability of our norovirus and COVID-19 vaccine candidates to be used repeatedly as boosters to extend protection in those previously vaccinated with Vaxart candidate vaccines.”
\u00a0
Key metrics identified in the boosting study were as follows:\u00a0<\/p>\n